Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wheeler

Showing results (1011-1020 of 1,217) with videos related to

Pageof 122
Sort By:
The Lancet. Planetary Health|April 5, 2024
Ambient heat exposure and kidney function in patients with chronic kidney disease: a post-hoc analysis of the DAPA-CKD trialZhiyan Zhang, Hiddo J L Heerspink, Glenn M Chertow, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 29, 2023
Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney FunctionIain C Macdougall, Piotr Ponikowski, Austin G Stack, et al.
JACC. Heart Failure|August 27, 2021
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart FailureJohn J V McMurray, David C Wheeler, Bergur V Stefánsson, et al.
Journal of the American Society of Nephrology : JASN|July 17, 2021
Effects of Dapagliflozin in Stage 4 Chronic Kidney DiseaseGlenn M Chertow, Priya Vart, Niels Jongs, et al.
Journal of the American Society of Nephrology : JASN|April 10, 2015
Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney DamageJames A P Tomlinson, Ben Caplin, Olga Boruc, et al.
European Heart Journal|April 1, 2021
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trialHiddo J L Heerspink, C David Sjöström, Niels Jongs, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2007
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overviewGlenn M Chertow, Lara B Pupim, Geoffrey A Block, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 23, 2020
Routine serum biomarkers, but not dual-energy X-ray absorptiometry, correlate with cortical bone mineral density in children and young adults with chronic kidney diseaseAlexander D Lalayiannis, Nicola J Crabtree, Charles J Ferro, et al.
Journal of the American Society of Nephrology : JASN|April 2, 2026
Association of Urinary Epidermal Growth Factor with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 InhibitionErik Moedt, Akihiko Koshino, Niels Jongs, et al.
Journal of the American Society of Nephrology : JASN|October 1, 2020
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A <i>Post</i><i>Hoc</i> Analysis from the CREDENCE TrialMegumi Oshima, Brendon L Neuen, JingWei Li, et al.
Pageof 122

Showing results (1011-1020 of 1,217) with videos related to

Sort By:
Pageof 122
The Lancet. Planetary Health|April 5, 2024
Ambient heat exposure and kidney function in patients with chronic kidney disease: a post-hoc analysis of the DAPA-CKD trialZhiyan Zhang, Hiddo J L Heerspink, Glenn M Chertow, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 29, 2023
Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney FunctionIain C Macdougall, Piotr Ponikowski, Austin G Stack, et al.
JACC. Heart Failure|August 27, 2021
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart FailureJohn J V McMurray, David C Wheeler, Bergur V Stefánsson, et al.
Journal of the American Society of Nephrology : JASN|July 17, 2021
Effects of Dapagliflozin in Stage 4 Chronic Kidney DiseaseGlenn M Chertow, Priya Vart, Niels Jongs, et al.
Journal of the American Society of Nephrology : JASN|April 10, 2015
Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney DamageJames A P Tomlinson, Ben Caplin, Olga Boruc, et al.
European Heart Journal|April 1, 2021
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trialHiddo J L Heerspink, C David Sjöström, Niels Jongs, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2007
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overviewGlenn M Chertow, Lara B Pupim, Geoffrey A Block, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 23, 2020
Routine serum biomarkers, but not dual-energy X-ray absorptiometry, correlate with cortical bone mineral density in children and young adults with chronic kidney diseaseAlexander D Lalayiannis, Nicola J Crabtree, Charles J Ferro, et al.
Journal of the American Society of Nephrology : JASN|April 2, 2026
Association of Urinary Epidermal Growth Factor with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 InhibitionErik Moedt, Akihiko Koshino, Niels Jongs, et al.
Journal of the American Society of Nephrology : JASN|October 1, 2020
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A <i>Post</i><i>Hoc</i> Analysis from the CREDENCE TrialMegumi Oshima, Brendon L Neuen, JingWei Li, et al.
Pageof 122